Skip to main content
CDC Website

Educational Organizations/Institutions

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR).

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)

This funding opportunity announcement (FOA)is a part of NIDAs Racial Equity Initiative.This multi-year,multi-pronged effort to address racial and ethnic inequities in NIDA's research portfolio. This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and ethnic minority populations in substance use, addiction, and related health consequences, including HIV.

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities.

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities.

Next Generation Multipurpose Prevention Technologies

The objective of this Funding Opportunity Announcement (FOA) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages.

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B, Hepatitis C and Tuberculosis).

Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)

Stimulant use has been increasing among opioid users since 2016, based on overdose data and this makes control of the opioid epidemic more difficult, as it occurs in addition to the continuing influx of fentanyl and related compounds. Stimulant/opioid users present unfamiliar clinical issues to providers and experienced providers often find polysubstance users less motivated to address stimulant use. Stimulant use also has continued to account for a substantial fraction of HIV cases among gay men and other MSM.

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies t